Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06762925
Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment
Sponsor: Xijing Hospital
View on ClinicalTrials.gov
Summary
This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
450
Start Date
2025-01-30
Completion Date
2026-06-01
Last Updated
2025-01-08
Healthy Volunteers
No
Interventions
OTHER
No Interventions
No Interventions